GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
Portfolio Pulse from
Law firm Levi & Korsinsky has filed a class action securities lawsuit against GSK, alleging the company misled investors about Zantac's potential cancer risks between February 2020 and August 2022. The lawsuit claims GSK knew about NDMA sources for decades before withdrawing the drug from the market, despite representations to investors about regulatory correspondence and safety.
March 21, 2025 | 10:00 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The class action lawsuit could result in significant financial liability and potential stock price impact for GSK, alleging deliberate misrepresentation about Zantac's safety and NDMA risks.
The lawsuit alleges systematic misrepresentation about Zantac's safety, which could lead to substantial financial penalties, legal costs, and potential investor trust erosion.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100